Enhancing precision in iPSC Allogeneic Cell Therapy through advanced gene-editing strategies

Induced pluripotent stem cells (iPSCs) have recently emerged as a promising avenue for advancing allogeneic cell therapies. Through the integration of gene-editing technologies, iPSCs offer distinct advantages over conventional donor-derived allogeneic cell therapies. Yet the process of introducing multiple genetic alterations using CRISPR technology presents challenges, particularly within sensitive iPSC environments. Efficient delivery of CRISPR components proves challenging in iPSCs due to their lower transfection and editing efficiencies compared to other cell types. Furthermore, it is imperative to maintain the pluripotent state of iPSCs throughout the gene-editing process. In addition, isolating individual cells and establishing clonal cell populations with desired genetic modifications presents a significant hurdle in genome-editing procedures for iPSCs. This article summarizes the challenges of employing gene-editing techniques for the development of iPSC-derived allogeneic cell therapies.